Breaking News Instant updates and real-time market news.

ALBO

Albireo Pharma

$34.41 /

+0.11 (+0.32%)

06:04
06/21/21
06/21
06:04
06/21/21
06:04

Albireo Pharma announces expanded Phase 3 data on Bylvay

Albireo Pharma announced new data in nine accepted abstracts to be presented at EASL International Liver Congress 2021 on June 23 - 26. The company said, "Data being presented demonstrate Albireo's leading position in the science of bile acid modulation with further evidence of efficacy and tolerability of Bylvay, as well as advancement in the characterization of A3907 in adult liver disease. Highlights from the Phase 3 PEDFIC studies show further evidence of a sustained and durable effect with Bylvay, while also showing improvements in sleep, growth and hepatic parameters in patients with progressive familial intrahepatic cholestasis. The Company will also have a presentation and poster on Phase 1 candidate, A3907, with pre-clinical data showing efficacy on markers of cholestatic disease." Bylvay is a potent, once-daily, non-systemic ileal bile acid transport inhibitor currently being developed for the treatment of PFIC, biliary atresia, and Alagille syndrome. PEDFIC 1 was the first and largest, global, pivotal Phase 3 study conducted in PFIC, which evaluated the efficacy and tolerability of Bylvay in reducing pruritus and serum bile acids in a randomized, double-blind, placebo-controlled trial, and PEDFIC 2 is a long-term, open-label Phase 3 extension study. Data being presented includes a pooled analysis of 77 patients treated with Bylvay. Key findings include: Affirms Improvement in Clinically Meaningful Endpoints: Patients with PFIC treated with Bylvay for up to 48 weeks experienced clinically meaningful effects on serum bile acids, pruritus, growth and sleep parameters. At baseline, sBAs score was 250 mumol/L and pruritus score was 2.9. Four weeks after starting Bylvay, sBAs had decreased by 88 mumol/L and pruritus score decreased by 0.7. At the end of the analysis period, sBAs had decreased from baseline by 213 mumol/L in patients with available data and pruritus score dropped by 1.4. Height Z scores increased from -1.9 at baseline to -0.8 at week48 and similar improvements were observed for weight Z scores. Bylvay-treated patients had changes from baseline to weeks 37-48 in observer-reported percentage of days seeing blood due to reductions in scratching, needing help falling asleep, needing soothing and sleeping with caregiver. The observed safety and tolerability profile of Bylvay was consistent across studies, treatment groups and doses. No drug-related serious adverse events were reported in either PEDFIC 1 or PEDFIC 2. One patient in PEDFIC 1 and 3 patients in PEDFIC 2 treated with Bylvay withdrew due to an adverse event. There were low numbers of gastrointestinal adverse events; treatment-related diarrhea/frequent bowel movements was reported in 10% of Bylvay treated patients in PEDFIC 1 and 5% of placebo-treated patients. Rapid and Durable Effect: Results of this pooled analysis in children with PFIC from two Phase 3 studies show that Bylvay was associated with rapid reductions in serum bile acid levels and improvements in pruritus severity, with durable clinical benefits sustained through 48 weeks of treatment. By week 4, 31% of patients treated with Bylvay were serum bile acid responders. At weeks 46-48, 67% of patients were serum bile acid responders. From baseline to week 4 and baseline to week 48, the proportion of positive pruritus assessments at the patient level with Bylvay treatment was 54% and 66%, respectively. A rapid reduction in autotaxin levels was observed by week 4, with a mean change from baseline in autotaxin with Bylvay treatment of -712 ng/mL. Continued reduction in autotaxin was observed at 48 weeks, with a mean change from baseline of -2,298 ng/mL. Mean change from baseline in plasma C4 with Bylvay treatment was 10 ng/mL at week 4 and 31 ng/mL at 48 weeks. Responders Showed Effects on Cholestasis-Related Parameters: Patients with PFIC who responded to Bylvay treatment had sustained improvements in cholestasis-related parameters over 48 weeks that were not observed to the same extent in treatment non-responders. Rates of sBA responders and sBA or pruritus responders were 31% and 57%, respectively, at weeks 0-24, 48% and 60% at weeks 25-36, and 59% and 65% at weeks 37-48. Among all Bylvay-treated patients, mean change from baseline to week 48 in alanine aminotransferase was -82 U/L and total bilirubin -18 mumol/L. Improvement in Multiple Sleep Parameters: Patients with PFIC and Bylvay treatment response had substantial improvements in caregiver- and clinician-reported sleep parameters; these effects occurred rapidly and continued over time. Mean decreases in caregiver-reported percentage of days with scratching associated with bleeding, needing help falling asleep, and needing soothing were greater among responders vs. non-responders. At 48 weeks, clinicians and caregivers reported that greater than or equal to88% of responders had moderately or very much better sleep since starting Bylvay. Pretreatment Serum Bile Acid Parameters and Predictability of Response: Response to Bylvay treatment in patients in PEDFIC 1 was not associated with pretreatment serum concentrations of total, primary or secondary bile acids, or with C4 levels. Among the 42 patients treated with Bylvay in PEDFIC 1, 32 used concomitant UDCA, while 10 did not. Overall, 40 patients had available UDCA concentration data. In patients who used UDCA, the median baseline UDCA concentration was 55.6 mumol/L. In those who did not use UDCA, the median baseline UDCA concentration was 0.2 mumol/L

  • 23

    Jun

  • 29

    Jun

  • 20

    Jul

  • 10

    Sep

ALBO Albireo Pharma
$34.41 /

+0.11 (+0.32%)

05/24/21 H.C. Wainwright
H.C. Wainwright ups Albireo target to $76 on positive CHMP opinion for Bylvay
05/24/21 Baird
Albireo Pharma could be an attractive takeout candidate, says Baird
05/21/21 Piper Sandler
Albireo gets 'strong win' with positive CHMP opinion, says Piper Sandler
03/26/21 Jefferies
Albireo Pharma price target raised to $82 after doctor survey at Jefferies

TODAY'S FREE FLY STORIES

Hot Stocks
Aerojet Rocketdyne conducts 'solid rocket motor test firing' at Arkansas site » 19:42
09/22/21
09/22
19:42
09/22/21
19:42
AJRD

Aerojet Rocketdyne

$41.32 /

-0.665 (-1.58%)

Aerojet Rocketdyne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

04/27/21 Truist
Aerojet Rocketdyne price target lowered to $51 from $56 at Truist
01/07/21 Jefferies
Jefferies downgrades Aerojet Rocketdyne to Hold, sees higher bid as unlikely
01/07/21 Jefferies
Aerojet Rocketdyne downgraded to Hold from Buy at Jefferies
12/22/20 Credit Suisse
Lockheed Martin price target raised to $409 from $400 at Credit Suisse
AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

Hot Stocks
Buenaventura announces strike at Uchucchacua Mine » 19:38
09/22/21
09/22
19:38
09/22/21
19:38
BVN

Buenaventura

$7.53 /

+0.17 (+2.31%)

Compania de Minas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BVN Buenaventura
$7.53 /

+0.17 (+2.31%)

03/08/21 Citi
Buenaventura price target lowered to $12 from $13 at Citi
12/15/20 Goldman Sachs
Buenaventura downgraded to Neutral from Buy at Goldman Sachs
Syndicate
Brilliant Earth 8.33M share IPO priced at $12.00 » 19:25
09/22/21
09/22
19:25
09/22/21
19:25
BRLT

Brilliant Earth

/

+

The deal size was reduced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Conference/Events
Yum China to hold virtual investor day » 19:25
09/22/21
09/22
19:25
09/22/21
19:25
YUMC

Yum China

$54.43 /

+0.3 (+0.55%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

09/20/21 Stifel
Starbucks price target trimmed to $130 at Stifel after Yum China disclosures
09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

Hot Stocks
Ingredion raises quarterly dividend to 65c per share from 64c » 19:22
09/22/21
09/22
19:22
09/22/21
19:22
INGR

Ingredion

$87.47 /

+0.305 (+0.35%)

The dividend is payable…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INGR Ingredion
$87.47 /

+0.305 (+0.35%)

INGR Ingredion
$87.47 /

+0.305 (+0.35%)

09/10/21 Lake Street
S&W Seed pact with Ingredion a 'potential needle-mover,' says Lake Street
05/05/21 Stephens
Stephens downgrades Ingredion to Equal Weight on lower beat and raise potential
05/05/21 Stephens
Ingredion downgraded to Equal Weight from Overweight at Stephens
INGR Ingredion
$87.47 /

+0.305 (+0.35%)

INGR Ingredion
$87.47 /

+0.305 (+0.35%)

Syndicate
Sovos Brands 23.3M share IPO priced at $12.00 » 19:21
09/22/21
09/22
19:21
09/22/21
19:21
SOVO

Sovos Brands

/

+

The deal priced below the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Syndicate
Sterling Check 14.285M share IPO priced at $23.00 » 19:10
09/22/21
09/22
19:10
09/22/21
19:10
STER

Sterling Check

/

+

The deal priced above the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Hot Stocks
Amazon Web Services to open data centers in New Zealand » 18:53
09/22/21
09/22
18:53
09/22/21
18:53
AMZN

Amazon.com

$3,380.08 /

+33.19 (+0.99%)

Amazon Web Services…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

Hot Stocks
TScan Therapeutics director buys 5K shares of common stock » 18:52
09/22/21
09/22
18:52
09/22/21
18:52
TCRX

TScan Therapeutics

$6.19 /

-0.23 (-3.58%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
08/10/21 Morgan Stanley
TScan Therapeutics initiated with an Overweight at Morgan Stanley
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

  • 16
    Jul
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

Hot Stocks
Amplitude Healthcare Acquisition Corp stockholders approve Jasper combination » 18:42
09/22/21
09/22
18:42
09/22/21
18:42
AMHC

Amplitude Healthcare Acquisition Corp

$10.22 /

-0.28 (-2.67%)

Amplitude Healthcare…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMHC Amplitude Healthcare Acquisition Corp
$10.22 /

-0.28 (-2.67%)

Syndicate
Inotiv prices upsized $125M convertible senior note offering » 18:39
09/22/21
09/22
18:39
09/22/21
18:39
NOTV

Inotiv

$34.21 /

-15.715 (-31.48%)

The initial conversion…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

08:43 Today Craig-Hallum
Inotiv price target raised to $57 from $45 at Craig-Hallum
09/20/21 Craig-Hallum
Craig-Hallum bullish on Inotiv, initiates with a Buy
09/20/21 Craig-Hallum
Inotiv initiated with a Buy at Craig-Hallum
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

  • 21
    Apr
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

Recommendations
Gazprom price target raised to $12 from $10.50 at Goldman Sachs » 18:33
09/22/21
09/22
18:33
09/22/21
18:33
OGZPY

Gazprom

$9.29 /

+0.13 (+1.42%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OGZPY Gazprom
$9.29 /

+0.13 (+1.42%)

06/25/21 UBS
Gazprom upgraded to Buy on higher gas prices at UBS
06/25/21 UBS
Gazprom upgraded to Buy from Neutral at UBS
06/10/21 Erste Group
Gazprom upgraded to Hold from Sell at Erste Group
12/23/20 JPMorgan
Gazprom upgraded to Overweight from Neutral at JPMorgan
Upgrade
Lukoil upgraded to Buy from Neutral at Goldman Sachs » 18:30
09/22/21
09/22
18:30
09/22/21
18:30
LUKOY

Lukoil

$92.00 /

+1.49 (+1.65%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LUKOY Lukoil
$92.00 /

+1.49 (+1.65%)

07/07/21 Renaissance Capital
Lukoil downgraded to Hold from Buy at Renaissance Capital
02/09/21 VTB Capital
Lukoil upgraded to Buy from Hold at VTB Capital
11/27/20 VTB Capital
Lukoil downgraded to Hold from Buy at VTB Capital
Hot Stocks
Unity Software CEO: At our core we are SAS company » 18:24
09/22/21
09/22
18:24
09/22/21
18:24
U

Unity Software

$133.51 /

+2.49 (+1.90%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

09/10/21 Wedbush
Wedbush says Apple injunction could boost earnings for mobile game makers
08/31/21 Macquarie
Macquarie starts 'one-of-a-kind' Unity Software at Outperform
08/31/21 Macquarie
Unity Software initiated with an Outperform at Macquarie
08/11/21 Goldman Sachs
Unity Software initiated with a Buy at Goldman Sachs
U Unity Software
$133.51 /

+2.49 (+1.90%)

  • 08
    Feb
U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

On The Fly
Fly Intel: After-Hours Movers » 18:23
09/22/21
09/22
18:23
09/22/21
18:23
BB

BlackBerry

$9.56 /

+0.185 (+1.97%)

, FUL

H.B. Fuller

$60.44 /

+0.55 (+0.92%)

, MRM

Medirom Healthcare

$7.40 /

+0.15 (+2.07%)

, HRMY

Harmony Biosciences

$37.49 /

-1.09 (-2.83%)

, AVDL

Avadel Pharmaceuticals

$8.19 /

+0.065 (+0.80%)

, SAGE

Sage Therapeutics

$44.31 /

-0.895 (-1.98%)

, ARD

Ardagh Group

$24.65 /

+0.7 (+2.92%)

, JAZZ

Jazz Pharmaceuticals

$129.60 /

+0.36 (+0.28%)

, EAR

Eargo

$21.68 /

-0.39 (-1.77%)

, SYBX

Synlogic

$3.52 /

-0.04 (-1.12%)

, SCS

Steelcase

$13.35 /

+0.23 (+1.75%)

, REXR

Rexford Industrial

$60.18 /

+0.02 (+0.03%)

, KBH

KB Home

$40.95 /

+0.285 (+0.70%)

Check out this evening's…

ShowHide Related Items >><<
BB BlackBerry
$9.56 /

+0.185 (+1.97%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Canaccord
BlackBerry upgraded to Hold from Sell at Canaccord
06/25/21
Fly Intel: Top five analyst downgrades
06/25/21 TD Securities
BlackBerry downgraded to Reduce from Hold at TD Securities
FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

08/31/21 Citi
MasTec added to 'Value Creators' list at Citi, H.B. Fuller removed
06/25/21
Fly Intel: Top five analyst downgrades
06/25/21 Deutsche Bank
H.B. Fuller price target raised to $67 from $65 at Deutsche Bank
06/25/21 Citi
H.B. Fuller downgraded to Neutral from Buy at Citi
MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

16:22 Today Needham
Harmony Biosciences initiated with a Buy at Needham
03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

16:22 Today Needham
Avadel Pharmaceuticals initiated with a Buy at Needham
08/10/21 H.C. Wainwright
Avadel Pharmaceuticals approvability concerns 'overblown,' says H.C. Wainwright
03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

16:27 Today Needham
Sage Therapeutics initiated with a Buy at Needham
08/04/21 RBC Capital
Sage Therapeutics price target lowered to $55 from $60 at RBC Capital
08/04/21 H.C. Wainwright
Sage Therapeutics price target lowered to $80 from $86 at H.C. Wainwright
07/27/21 Canaccord
Sage Therapeutics price target lowered to $96 from $119 at Canaccord
ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

09/01/21 Citi
Ardagh Group resumed with a Buy at Citi
08/26/21
Fly Intel: Top five analyst initiations
08/26/21 Deutsche Bank
Ardagh Group resumed with a Buy at Deutsche Bank
05/26/21
Fly Intel: Top five analyst downgrades
JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

16:24 Today Needham
Jazz Pharmaceuticals initiated with a Buy at Needham
16:22 Today Needham
Avadel Pharmaceuticals initiated with a Buy at Needham
07/23/21 RBC Capital
Jazz Pharmaceuticals price target raised to $216 from $190 at RBC Capital
07/15/21 JPMorgan
JPMorgan stays bullish on Jazz Pharmaceuticals after physician survey
EAR Eargo
$21.68 /

-0.39 (-1.77%)

07/12/21 William Blair
William Blair says Biden exeuctive order not 'thesis-changer' for Eargo
07/09/21 Wells Fargo
Eargo selloff on White House order unwarranted, says Wells Fargo
06/22/21 Wells Fargo
Eargo5 launch appears to be on track, says Wells Fargo
05/13/21 Wells Fargo
Eargo price target lowered to $52 from $68 at Wells Fargo
SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

09/20/21 Chardan
Synlogic phenylketonuria data 'encouraging,' says Chardan
09/20/21 Piper Sandler
Synlogic price target raised to $9 at Piper Sandler on positive SynPHEny data
07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
SCS Steelcase
$13.35 /

+0.23 (+1.75%)

05/11/21 Berenberg
Berenberg starts 'market leader' Steelcase at Buy
05/11/21 Berenberg
Steelcase initiated with a Buy at Berenberg
05/07/21 Benchmark
Benchmark upgrades Steelcase to Buy on signs of recovery in commercial furniture
05/07/21 Benchmark
Steelcase upgraded to Buy from Hold at Benchmark
REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

08/10/21 Wells Fargo
Rexford Industrial price target raised to $65 from $58 at Wells Fargo
07/19/21 Capital One
Rexford Industrial upgraded to Overweight from Equalweight at Capital One
06/07/21 Wells Fargo
Rexford Industrial price target raised to $58 from $51 at Wells Fargo
10/28/20 Berenberg
Rexford Industrial initiated with a Buy at Berenberg
KBH KB Home
$40.95 /

+0.285 (+0.70%)

07/19/21
Fly Intel: Top five analyst upgrades
07/19/21 Seaport Global
KB Home upgraded to Buy from Neutral at Seaport Global
06/24/21 RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
BB BlackBerry
$9.56 /

+0.185 (+1.97%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

  • 23
    Sep
  • 23
    Sep
  • 25
    May
  • 16
    Apr
  • 29
    Dec
  • 02
    Dec
  • 16
    Oct
BB BlackBerry
$9.56 /

+0.185 (+1.97%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

Hot Stocks
Axonics Medtronic provides update on inter partes review proceedings » 18:14
09/22/21
09/22
18:14
09/22/21
18:14
AXNX

Axonics

$69.84 /

+0.56 (+0.81%)

, MDT

Medtronic

$128.90 /

+1 (+0.78%)

Axonics (AXNX) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AXNX Axonics
$69.84 /

+0.56 (+0.81%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

08/06/21 Barclays
Axonics price target raised to $79 from $74 at Barclays
08/06/21 Piper Sandler
Axonics price target raised to $78 from $75 at Piper Sandler
07/16/21 Barclays
Axonics recall of Bulkamid is not material, says Barclays
07/12/21
Fly Intel: Top five analyst initiations
MDT Medtronic
$128.90 /

+1 (+0.78%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
AXNX Axonics
$69.84 /

+0.56 (+0.81%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

  • 12
    May
MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

Periodicals
FDA set to authorize Pfizer booster shots Wednesday, Bloomberg says » 18:10
09/22/21
09/22
18:10
09/22/21
18:10
PFE

Pfizer

$43.95 /

+0.04 (+0.09%)

, BNTX

BioNTech

$339.40 /

-2.11 (-0.62%)

The FDA is slated to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

08/27/21 UBS
BioNTech price target raised to $300 from $111 at UBS
08/20/21 Canaccord
BioNTech price target raised to $450 from $240 at Canaccord
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

Hot Stocks
Immunocore publishes phase 3 data comparing tebentafusp with investigator choice » 18:05
09/22/21
09/22
18:05
09/22/21
18:05
IMCR

Immunocore

$35.88 /

-0.42 (-1.16%)

The company states:…

The company states: "Immunocore announces that data from a phase 3 randomized trial comparing tebentafusp with investigator's choice in first-line metastatic uveal melanoma has been published in The New England Journal of Medicine. The paper concluded that tebentafusp is the first systemic treatment to show a survival benefit in mUM and should become a new treatment option for this poor prognosis disease. Results from the randomized, open-label, phase 3 trial of tebentafusp vs. investigator's choice in previously untreated HLA-A*02:01-positive patients with mUM demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment in mUM. The OS Hazard Ratio in the intent-to-treat population favored tebentafusp, HR=0.51. Treatment-related adverse events were manageable and consistent with the proposed mechanism. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA and Promising Innovative Medicine designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. Immunocore's biologics license application for approval of tebentafusp for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma was recently accepted by the FDA. In addition, the European Medicine Agency's Committee for Medicinal Products for Human Use accepted Immunocore's Marketing Authorisation Application."

ShowHide Related Items >><<
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

  • 05
    Feb
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

Hot Stocks
Yum China and Lavazza to accelerate expansion of Lavazza cafes in China » 18:05
09/22/21
09/22
18:05
09/22/21
18:05
YUMC

Yum China

$54.43 /

+0.3 (+0.55%)

Yum China and Luigi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

09/20/21 Stifel
Starbucks price target trimmed to $130 at Stifel after Yum China disclosures
09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

Hot Stocks
AbCellera, Everest Medicines announce multi-target collaboration » 18:02
09/22/21
09/22
18:02
09/22/21
18:02
ABCL

AbCellera

$21.34 /

+0.265 (+1.26%)

AbCellera and Everest…

AbCellera and Everest Medicines have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest's portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology. The collaboration will leverage AbCellera's technology stack, including sourcing fully humanized antibodies from the Trianni Mouse, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform. Everest will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.

ShowHide Related Items >><<
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

  • 11
    Dec
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

Hot Stocks
Amazon partners with Billie Eilish over limited-edition Echo Studio » 17:50
09/22/21
09/22
17:50
09/22/21
17:50
AMZN

Amazon.com

$3,380.08 /

+33.19 (+0.99%)

Amazon has teamed up with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

General news
Treasury Market Summary » 17:50
09/22/21
09/22
17:50
09/22/21
17:50
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: it was a rather typical Fed day. The Treasury market was predictably quiet heading into the FOMC results and the Powell presser. And it was just as predictably volatile in the aftermath. Uncertainties over the potential hawkishness of the dots and the dovishness of the policy spin from the Fed Chair counterbalanced into the afternoon, leaving rates little changed. After the FOMC indicated QE tapering was likely "soon," the bond market turned mixed with the front end under pressure and the long end rallying, flattening the curve to 106 bps in the process. On the other hand, Wall Street was in rally mode from the get go. In spite of the looming FOMC, investors took solace from easing in the China Evergrande bond debacle. Dip buying amid heavily oversold conditions helped propel all the indexes better than 1% gains, though they faded following the FOMC. The Dow and NASDAQ were up 1% at the close, with the S&P 500 0.95% firmer.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Grinrod Shipping 1.842M share Spot Secondary; price range $13.50-$14.00 » 17:47
09/22/21
09/22
17:47
09/22/21
17:47
GRIN

Grinrod Shipping

$15.57 /

-0.92 (-5.58%)

Jefferies is acting as…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GRIN Grinrod Shipping
$15.57 /

-0.92 (-5.58%)

  • 23
    Sep
Conference/Events
Resonant to hold a webinar » 17:43
09/22/21
09/22
17:43
09/22/21
17:43
RESN

Resonant

$2.55 /

+0.06 (+2.41%)

Management to hold a…

Management to hold a webinar entitled, "5G Insights in Japan" on September 29 at 9 pm. Webcast Link

ShowHide Related Items >><<
RESN Resonant
$2.55 /

+0.06 (+2.41%)

RESN Resonant
$2.55 /

+0.06 (+2.41%)

07/27/21 Benchmark
Benchmark starts Resonant at Buy with $6 price target
07/27/21 Benchmark
Resonant initiated with a Buy at Benchmark
RESN Resonant
$2.55 /

+0.06 (+2.41%)

Hot Stocks
Beneficial owner of Civeo Lance Torgerson sells $370K in shares » 17:41
09/22/21
09/22
17:41
09/22/21
17:41
CVEO

Civeo

$22.76 /

+0.86 (+3.93%)

Beneficial owner of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CVEO Civeo
$22.76 /

+0.86 (+3.93%)

CVEO Civeo
$22.76 /

+0.86 (+3.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.